|By PR Newswire||
|February 7, 2014 07:44 AM EST||
DUBLIN, Feb. 7, 2014 PRNewswire/ --Research and Markets (http://www.researchandmarkets.com/research/bt6gxm/biomarkers_market) has announced the addition of the "Biomarkers Market - Discovery Technologies , Validation Services, Applications & Diseases - Global Trends & Forecasts (2013 - 2018)" report to their offering.
Biomarkers comprise definite cells, genes, molecules, gene products, enzymes, or hormones which are objectively measured as an indicator of typical biological processes, pathogenic processes, or pharmacologic response to a therapeutic intrusion. Major application areas of biomarkers are early disease diagnosis and prevention, drug target recognition, and drug discovery and development. The global market showcases high growth potential in the near future. This market is expected to grow at a CAGR of 18.5% from 2013 to 2018, to reach $40.8 billion by 2018.
The global market has been segmented into biomarker discovery technologies, biomarker services, applications, and disease indications. The biomarker discovery technologies are classified as omics technology, imaging technology, and bioinformatics. Omics technology, which includes proteomics, genomics, transcriptomics, and metabolomics, accounts for the largest share of the biomarker discovery technology market. The biomarkers services market is classified into sample preparation, assay development, and biomarker validation and testing services. Biomarker applications market has been segmented as drug discovery and development, molecular diagnostics, and personalized medicine. Based on type of diseases, the biomarker disease indication market has been classified as oncology, cardiology, neurology, and other diseases (HIV, renal disorders, diabetes, arthritis, and tuberculosis).
Globally, the biomarkers market is witnessing a transformation and is expected to grow at a high growth rate in the coming years. The growth in the market will be primarily driven by advancements in discovery technologies, government initiatives and grants for biomarker research activities, and rising demand for personalized medicine. The incidence and prevalence of chronic diseases such as cancer, cardiac diseases, and diabetes is increasing globally and hence, it is crucial to develop new preventive and diagnostics treatments. Since, biomarkers play a significant role in development of preventive and diagnostic tests and drugs, the demand of biomarkers is expected to increase rapidly.
Over the past few years, the biomarkers industry has been witnessing increasing number of contracts and partnership agreements among market players for the development of novel biomarkers. Major research on biomarkers is taking place in the field of oncology. Recent developments of companies such as Thermo Fisher Scientific, Inc. (U.S.), QIAGEN N.V. (Netherlands), Roche Diagnostics (Switzerland), Hologic, Inc. (U.S.), and Johnson & Johnson (U.S.) have exhibited inclination towards agreements and partnerships, in accordance to their key strategy to expand their market share and geographical presence.
Key Topics Covered:
2 Executive Summary
3 Market Overview
4 Global Biomarkers Market, By Discovery Technologies
5 Services Market Of Biomarkers
6 Biomarkers Application Market
7 Biomarkers Indication Market
8 Geographical Analysis
9 Competitive Landscape
10 Company Profiles
- Abbott Laboratories
- Abcodia Ltd
- Affymetrix Inc
- Agilent Technologies Inc
- Amgen Inc
- Astrazeneca Plc
- Augurex Life Sciences Corp
- Aushon Biosystems Inc
- Bayer Ag
- Beckman Coulter Inc
- Biocrates Life Sciences AG
- Biomarkers Strategies
- Biosystems International
- Bristol-Myers Squibb
- Caprion Proteomics Inc
- Crescendo Bioscience
- Eisai Co Ltd
- Epiontis GMBH
- Epistem Holdings PLC
- Eurogentec SA
- Evotec AG
- Glaxosmithkline PLC
- Johnson & Johnson
- Merck & Co
- Micromedic Technologies Ltd
- Myriad Genetics Inc
- Nextgen Sciences Inc
- Novartis International AG
- Ocimum Biosolutions Ltd
- Pacific Biomarkers Inc
- Pfizer Inc
- Pronota NV
- Proteome Sciences Plc
- Qiagen Nv
- Quintiles Transnational Corporation
- Roche Diagnostics Limited
- Siemens Healthcare
- Trans-Hit Biomarkers Inc
- Vermillion Inc
For more information visit http://www.researchandmarkets.com/research/bt6gxm/biomarkers_market
Media Contact: Laura Wood , +353-1-481-1716, [email protected]
Sep. 29, 2016 01:00 PM EDT Reads: 1,685
Sep. 29, 2016 12:45 PM EDT Reads: 5,130
Sep. 29, 2016 12:30 PM EDT Reads: 1,743
Sep. 29, 2016 12:30 PM EDT Reads: 1,750
Sep. 29, 2016 12:00 PM EDT Reads: 422
Sep. 29, 2016 12:00 PM EDT Reads: 3,134
Sep. 29, 2016 11:45 AM EDT Reads: 2,583
Sep. 29, 2016 11:30 AM EDT Reads: 2,146
In this strange new world where more and more power is drawn from business technology, companies are effectively straddling two paths on the road to innovation and transformation into digital enterprises. The first path is the heritage trail – with “legacy” technology forming the background. Here, extant technologies are transformed by core IT teams to provide more API-driven approaches. Legacy systems can restrict companies that are transitioning into digital enterprises. To truly become a lea...
Sep. 29, 2016 11:00 AM EDT Reads: 396
Sep. 29, 2016 11:00 AM EDT Reads: 3,511
Cloud computing is being adopted in one form or another by 94% of enterprises today. Tens of billions of new devices are being connected to The Internet of Things. And Big Data is driving this bus. An exponential increase is expected in the amount of information being processed, managed, analyzed, and acted upon by enterprise IT. This amazing is not part of some distant future - it is happening today. One report shows a 650% increase in enterprise data by 2020. Other estimates are even higher....
Sep. 29, 2016 11:00 AM EDT Reads: 4,164
The Jevons Paradox suggests that when technological advances increase efficiency of a resource, it results in an overall increase in consumption. Writing on the increased use of coal as a result of technological improvements, 19th-century economist William Stanley Jevons found that these improvements led to the development of new ways to utilize coal. In his session at 19th Cloud Expo, Mark Thiele, Chief Strategy Officer for Apcera, will compare the Jevons Paradox to modern-day enterprise IT, e...
Sep. 29, 2016 11:00 AM EDT Reads: 2,405
Sep. 29, 2016 11:00 AM EDT Reads: 300
Let’s face it, embracing new storage technologies, capabilities and upgrading to new hardware often adds complexity and increases costs. In his session at 18th Cloud Expo, Seth Oxenhorn, Vice President of Business Development & Alliances at FalconStor, discussed how a truly heterogeneous software-defined storage approach can add value to legacy platforms and heterogeneous environments. The result reduces complexity, significantly lowers cost, and provides IT organizations with improved efficienc...
Sep. 29, 2016 10:45 AM EDT Reads: 3,586
What are the new priorities for the connected business? First: businesses need to think differently about the types of connections they will need to make – these span well beyond the traditional app to app into more modern forms of integration including SaaS integrations, mobile integrations, APIs, device integration and Big Data integration. It’s important these are unified together vs. doing them all piecemeal. Second, these types of connections need to be simple to design, adapt and configure...
Sep. 29, 2016 10:45 AM EDT Reads: 451